This article is more than 5 years old. Information may no longer be current.
Array, Merck to collaborate on trial of binimetinib, pembrolizumab for metastatic colorectal cancer
Array BioPharma and Merck entered into a clinical trial collaboration agreement to evaluate binimetinib in combination with pembrolizumab for the treatment of patients with metastatic colorectal cancer who have microsatellite stable tumors.
Evidence from preclinical and clinical trials demonstrated that the immune activity of the anti–PD-1 therapy pembrolizumab (Keytruda, Merck) can be enhanced when combined with a MEK inhibitor, such as binimetinib (Array BioPharma).
“Array is excited to announce this partnership with Merck, an established leader in the field of immuno-oncology,” Ron Squarer, CEO of Array BioPharma, said in a company-issued press release. “Given the synergistic activity we have seen with our MEK inhibitor when combined with anti–PD-1 therapy in preclinical models, and based on emerging clinical data, we are optimistic that this combination holds great potential for cancer patients.”
The two companies will collaborate on a clinical trial designed to assess the efficacy and safety of the combination in patients with metastatic colorectal cancer who have microsatellite stable tumors.
The trial — expected to begin this year — will be designed to establish a recommended dose of binimetinib plus pembrolizumab. It also will explore the preliminary antitumor activity of several novel regimens. Results will help determine optimal approaches for further clinical development of these combinations.
Under the agreement, the trial will be sponsored by Merck.